Novel targeted therapies for eosinophilic disorders

被引：85

作者：

Wechsler, Michael E. ^{[1
]}

Fulkerson, Patricia C. ^{[2
]}

Bochner, Bruce S. ^{[3
]}

Gauvreau, Gail M. ^{[4
]}

Gleich, Gerald J. ^{[5
]}

Henkel, Tim ^{[6
]}

Kolbeck, Roland ^{[7
]}

Mathur, Sameer K. ^{[8
]}

Ortega, Hector ^{[9
]}

Patel, Jatin ^{[10
]}

Prussin, Calman ^{[11
]}

Renzi, Paolo ^{[12
]}

Rothenberg, Marc E. ^{[2
]}

Roufosse, Florence ^{[13
,14
]}

Simon, Dagmar ^{[15
]}

Simon, Hans-Uwe ^{[16
]}

Wardlaw, Andrew ^{[17
]}

Weller, Peter F. ^{[18
]}

Klion, Amy D. ^{[19
]}

机构：

[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA

[2] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, Baltimore, MD USA

[3] Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA

[4] McMaster Univ, Hamilton, ON L8S 4L8, Canada

[5] Univ Utah, Dept Dermatol & Med, Salt Lake City, UT USA

[6] Ceptaris Therapeut, Malvern, PA USA

[7] MedImmune Resp Inflammat & Autoimmun, Gaithersburg, MD USA

[8] Univ Wisconsin, Sch Med, Dept Med, Div Allergy Pulm & Crit Care, Madison, WI 53706 USA

[9] GlaxoSmithKline Res & Dev Ltd, Res Triangle Pk, NC USA

[10] GlaxoSmithKline Res & Dev Ltd, Uxbridge, Middx, England

[11] NIAID, Lab Allerg Dis, Bethesda, MD 20892 USA

[12] Univ Montreal, Notre Dame Hosp, Montreal, PQ H3C 3J7, Canada

[13] Univ Libre Bruxelles, Erasme Hosp, Dept Internal Med, Brussels, Belgium

[14] Univ Libre Bruxelles, Inst Med Immunol, Gosselies, Belgium

[15] Univ Hosp Bern, Dept Dermatol, Inselspital, Bern, Switzerland

[16] Univ Bern, Inst Pharmacol, CH-3012 Bern, Switzerland

[17] Univ Leicester, Inst Lung Hlth, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England

[18] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA

[19] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2012年 / 130卷 / 03期

基金：

美国国家卫生研究院;

关键词：

Hypereosinophilic syndromes; eosinophil-associated gastrointestinal disorders; eosinophilic esophagitis; Churg-Strauss syndrome; IL-5; mepolizumab; reslizumab; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; ANTI-IL-5 MEPOLIZUMAB THERAPY; CHURG-STRAUSS-SYNDROME; T-CELL POPULATION; AIRWAY INFLAMMATION; PERIPHERAL-BLOOD; ANTI-INTERLEUKIN-5; ANTIBODY; INHIBITORY RECEPTORS; ALEMTUZUMAB THERAPY; MONOCLONAL-ANTIBODY;

D O I：

10.1016/j.jaci.2012.07.027

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with HESs, additional agents with increased efficacy and decreased toxicity are sorely needed. The purpose of this review is to provide an overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy and to provide a summary of potential eosinophil-targeting agents, including those in development, in clinical trials, or approved for other disorders. (J Allergy Clin Immunol 2012;130:563-71.)

引用

页码：563 / 571

页数：9

共 50 条

[21] Novel targeted therapies of T cell lymphomas
Izykowska, Katarzyna
Rassek, Karolina
Korsak, Dorota
Przybylski, Grzegorz K.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
[22] Emerging Therapies for Eosinophilic Gastrointestinal Diseases
Peterson, Kathryn
Safroneeva, Ekaterina
Schoepfer, Alain
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (09): : 3276 - 3281
[23] Novel Targeted Therapies for Inflammatory Bowel Disease
Coskun, Mehmet
Vermeire, Severine
Nielsen, Ole Haagen
TRENDS IN PHARMACOLOGICAL SCIENCES, 2017, 38 (02) : 127 - 142
[24] Novel targeted therapies in head and neck cancer
Ferreira, Mariana B. A.
Lima, Joao Paulo S. N.
Cohen, Ezra E. W.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (03) : 281 - 295
[25] Novel Targeted Therapies in Ovarian and Uterine Carcinosarcomas
Han, Chanhee
Altwerger, Gary
Menderes, Gulden
Haines, Kaitlin
Feinberg, Jacqueline
Lopez, Salvatore
Manzano, Aranzazu
Varughese, Joyce
Santin, Alessandro D.
DISCOVERY MEDICINE, 2018, 25 (140) : 309 - 319
[26] Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs
Varricchi, Gilda
Bagnasco, Diego
Borriello, Francesco
Heffler, Enrico
Canonica, Giorgio W.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 16 (02) : 186 - 200
[27] Biologic Therapies Targeting Eosinophilic Gastrointestinal Diseases
Oshima, Tadayuki
INTERNAL MEDICINE, 2023, 62 (23) : 3429 - 3430
[28] Cardiotoxicity of novel HER2-targeted therapies
Sendur, Mehmet A. N.
Aksoy, Sercan
Altundag, Kadri
CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (08) : 1015 - 1024
[29] Psoriasis pathogenesis and the development of novel targeted immune therapies
Hawkes, Jason E.
Chan, Tom C.
Krueger, James G.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 140 (03) : 645 - 653
[30] Novel cytokine-targeted therapies and intestinal inflammation
Waldner, Maximilian J.
Neurath, Markus F.
CURRENT OPINION IN PHARMACOLOGY, 2009, 9 (06) : 702 - 707

← 1 2 3 4 5 →